JERSEY CITY, N.J.--(BUSINESS WIRE)--Lux Biosciences today announced that details from the ongoing phase 2/3 LUMINATE clinical program of the company’s investigational therapy for uveitis, Luveniq™ (oral formulation of voclosporin), will be the subject of a presentation at the 7th International Symposium on Uveitis. The Symposium, organized by the International Uveitis Study Group, is being held from September 9 – 12 in Lake Constance, Germany.
